Retinal specialists have a new therapy in their armoury: on January 24th 2007, the European Commission approved ranibizumab (Lucentis, Novartis) for the treatment of patients with wet age-related macular degeneration (AMD).
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.